Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level (STERPROSER)

Hopital Foch

Status

Completed

Conditions

Prostate Hyperplasia

Urinary Bladder Neoplasms

Treatments

Biological: steroids concentrations determination

Study type

Interventional

Funder types

Other

Identifiers

NCT02778243

2014-A00706-41 (Other Identifier)

2014/01

Details and patient eligibility

About

Patients followed in the Foch Hospital Urology Department (Suresnes): Patients justifying a prostatectomy.

Patients justifying prostatectomy together with the bladder (radical cystectomy for bladder cancer).
Patients with benign prostate hyperplasia who justified a prostatectomy. Compare serum sexual steroid concentrations and intra-tissue on healthy prostates and prostate adenoma, assess concentrations intra-tissue sex steroids on cancer metastasis prostate specific blood sample under study (30mL) will be performed preoperatively in Patients followed in Foch Hospital Urology Department (Suresnes), and a Removal of a fragment of prostate tissue or metastasis will be analyze.

Aim is to compare serum concentrations of sexual steroids and intra-tissue on healthy prostates and prostate adenomas compared to concentrations measured in patients operated for prostate cancer.

Full description

Steroids concentration will be determined using Gas chromatography-mass spectrometry. The analyzed steroids are :

FSH :Mul/ml LH: mUI/ml SHBG: µg/ml BT: ng/ml TT: ng/ml DHT: ng/ml DHEA: ng/ml D5: ng/ml D4: ng/ml E1: pg/ml E2 : pg/ml DHEA-S : µg/dl

Enrollment

107 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men aged over 18 years
Surgical indication justifying protatique prostatectomy, or complete prostatocystectomie, or removal of a metastasis of prostate cancer.
Patients affiliated to a social security scheme or benefiting from such a regime.
Patients who have given their consent to participate in writing

Exclusion criteria

Patient received local therapy or hormonal treatment (LHRH analogue, therapy blocking androgen receptors) before surgery.
Treatment reductase inhibitors 5ARI ongoing or stopped for less than 3 months before the intervention.
Patient included in another clinical trial inconsistent with the conduct of this research.
Patient receiving treatment that could interfere with hormone levels (Prednisone, Ketoconazole, Abiraterone, Finasteride, Dutasteride).